Released in 1998: 15 million transistors per chip The first 64-bit symmetric multiprocessor (SMP), POWER3 is completely compatible with the original POWER instruction set -- and compatible with the PowerPC instruction set as well. The POWER3 was designed for work on scientific and technical computing applications from aerospace and pharma to weather prediction. It features a data prefetch engine, non-blocking interleaved data cache, dual floating point execution units, and many other goodies. The POWER3-II reimplemented POWER3 using copper interconnects, delivering double the performance at about the same price. The achieved speeds were from 200MHz to 450 MHz.
POWER2POWER4POWER5POWER6POWER7 Released in September 1993 and in use until 1998: 15 million transistors per chip The POWER2 added a second floating-point unit (FPU) and more cache. ... IBM POWER4+ Released in 2001: 174 million transistors per processor A gigaprocessor incorporating 0. ... POWER is a RISC CPU architecture designed at IBM. The name, arguably, stands for Performance Optimization With Enhanced RISC. POWER series CPUs are used as the main CPU in many of IBMs servers, minicomputers, workstations, and supercomputers. ... This article needs to be wikified. ... POWER7 is a microprocessor currently under development at IBM Research as of April 2005. ...
The Mission of Power3 Medical is to discover new protein biomarkers with clinical and economic utility and use them to develop novel commercial screening and diagnostic tests that benefit clinicians, patients and families by enabling earlier disease detection and treatment.
Power3 Medical is committed to bringing the medical community and ultimately the public, breakthrough diagnostics and therapies aimed at improving healthcare, survival and quality of life (QOL) for patients and families.
Power3 Medical is a discovery machine for utilitarian biomarkers for use by standard diagnostic companies, pharma companies or used on a new platform developed in-house.
Power3 will own a minority interest of the new CRO, which is expected to be launched in the third or fourth quarter of 2007.
Rash said that for Power3 shareholders, the licensing of the company's technology to the CRO "has the potential to result in a strong revenue stream in the near and long term, which would allow us to move full-speed ahead to validate and commercialize technologies we've discovered and pioneered.
Power3 is becoming an emerging force in the proteomics community by developing and validating a process for reproducing protein biomarkers.
Feeds |
Contact